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Abstract
Introduction
Guidelines for the treatment of psychoses recommend antipsychotic monotherapy. Howev-
er, the rate of antipsychotic polytherapy has increased over the last decade, reaching up to
60% in some settings. Studies evaluating the costs and impact of antipsychotic polytherapy
in the health system are scarce.
Objective
To estimate the costs of antipsychotic polytherapy and its impact on public health costs in a
sample of subjects with psychotic disorders living in residential facilities in the city of Sao
Paulo, Brazil.
Method
A cross-sectional study that used a bottom-up approach for collecting costs data in a public
health provider´s perspective. Subjects with psychosis living in 20 fully-staffed residential
facilities in the city of Sao Paulo were assessed for clinical and psychosocial profile, severity
of symptoms, quality of life, use of health services and pharmacological treatment. The im-
pact of polytherapy on total direct costs was evaluated.
Results
147 subjects were included, 134 used antipsychotics regularly and 38% were in use of anti-
psychotic polytherapy. There were no significant differences in clinical and psychosocial
characteristics between polytherapy and monotherapy groups. Four variables explained
30% of direct costs: the number of antipsychotics, location of the residential facility, time liv-
ing in the facility and use of olanzapine. The costs of antipsychotics corresponded to 94.4%
of the total psychotropic costs and to 49.5% of all health services use when excluding ac-
commodation costs. Olanzapine costs corresponded to 51% of all psychotropic costs.
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Conclusion
Antipsychotic polytherapy is a huge economic burden to public health service, despite the
lack of evidence supporting this practice. Great variations on antipsychotic costs explicit the
need of establishing protocols for rational antipsychotic prescriptions and consequently op-
timising resource allocation. Cost-effectiveness studies are necessary to estimate the best
value for money among antipsychotics, especially in low and middle income countries.
Introduction
In the last decade, antipsychotic polytherapy has been subject of controversy and criticism in
the treatment of schizophrenia and related psychoses [1]. Different from psychotropic poly-
therapy (i.e., a combination of psychotropic drugs from different pharmacological classes),
which may be indicated for the management of comorbidities in any psychiatric illness or in
the treatment of mood disorders [2,3], the antipsychotic polytherapy (or polypharmacy) may
be defined as a concurrent use of more than one antipsychotic with the purpose of a better con-
trol of psychotic symptoms [4,5]. Basically all schizophrenia treatment guidelines recommend
the use of antipsychotic monotherapy and, as a second step, if there is no adequate response,
switching to a second antipsychotic in monotherapy. In case of two treatment failures, or in
some cases, three treatment failures, the patient is considered treatment-resistant, and the rec-
ommendation is the use of clozapine, the only approved antipsychotic for treatment-resistant
schizophrenia [6–9]. Antipsychotic polytherapy is usually recommended by the algorithms as
a last resource, as an attempt to augment clozapine effect [6–10], but even the combination
with clozapine has a weak evidence of efficacy [11].
In terms of efficacy, there is no antipsychotic, whether typical or atypical, with a clear supe-
riority over the others, with the exception of clozapine, which is more efficacious in cases of
treatment-resistant schizophrenia [12,13]. Antipsychotics differ substantially in side-effects
and currently they may be all equally considered first line treatment for psychosis, when only
clinical response is taken into account, as we observe in the treatment guidelines [6–8].
Given the fact that, with the exception of clozapine, all antipsychotics do not differ substan-
tially in terms of efficacy and virtually all guidelines recommend antipsychotic monotherapy
for the treatment of psychoses, it is noteworthy that the use of antipsychotic polytherapy has
increased [14–17].
According to a study based on chart review, most polypharmacy prescriptions have justifi-
able clinical rationales, such as refractoriness, problems of adherence, poor control of symptoms
and use of a second antipsychotic for other reasons [1]. In other cases, polypharmacy could re-
flect an attempt of augmentation therapy, or a treatment of different symptoms domains (e.g.,
cognitive or negative symptoms) or even prescribing habits [5]. However, there is some evidence
that it is reasonable to switch to monotherapy patients receiving polypharmacy, with benefits
such as weight loss [18] and decrease of side effects, risk of drug interactions and costs [10].
Whether clinically justifiable or not, antipsychotic polypharmacy has not proven superior
efficacy over monotherapy, and because it is so widely used, it is important to evaluate the eco-
nomic impact of this practice.
The costs and economic impact of antipsychotic polypharmacy are relevant for the budget
in mental health services [14]. Antipsychotic polytherapy represents a common prescribing
pattern for severely ill patients living in residential facilities [19], but it is associated with higher
health services costs and higher utilization of health services[20].
The Economic Impact of Antipsychotic Polytherapy
PLOS ONE | DOI:10.1371/journal.pone.0124791 April 8, 2015 2 / 13
Competing Interests: MK has acted as a consultant
for Abbott, Aché, Eurofarma, Genzyme, Glaxo-
Smithkline, Sankyo, Takeda and Uniao Quimica; has
received grant support from Roche and has received
travel support from Glaxo Smithkline in the last 2
years. AS has received travel support from EMS,
Libbs, Sanofi and Wyeth. The other authors had no
competing interests to declare. This does not alter the
authors' adherence to PLOS ONE policies on sharing
data and materials.
In the State of Sao Paulo, Brazil, six atypical and eight typical antipsychotics (including
two depot) are freely available in the public health system to all citizens. Despite some govern-
mental initiatives to elaborate treatment guidelines, the antipsychotic costs were not consid-
ered in the recommendations and no treatment algorithm was effectively implemented in the
mental health care system. There is a huge variation of costs among antipsychotics and a lack
of information about the costs of different patterns of antipsychotic prescription. According-
ly, we aimed to estimate the costs of antipsychotic polypharmacy and its impact on public
health care costs in a sample of patients with psychotic disorders living in residential facilities
in the city of Sao Paulo.
Methods
Study Design
A cross-sectional study was carried out in the city of Sao Paulo, from February 2011 to May
2012. This study is part of a research project that evaluated the direct costs of health services
for a sample of subjects discharged from long-term psychiatric hospitals.
Setting: Residential facilities were created in Brazil under public government funding in
2000, to support people discharged from long-term psychiatric hospitals. There are two types
of services: Residential facilities type 1, where six to eight people with mental disorders can live
independently, sharing a house in the community, with an off-site carer available in an on-call
basis, and Residential services type 2, for people with lower level of autonomy, in need of per-
manent care and with no family relationships. Type 2 is a fully-staffed home, with up to eight
residents living there under 24-hour supervision of two carers taking turns working in 12
hours daily-basis regime. Carers should support all residents' needs and also help on the psy-
chosocial rehabilitation process, in order to improve their autonomy and social skills. These
services are linked to a Center of Psychosocial Rehabilitation (CAPS), a mental health center
with specialists on clinical and psychosocial treatment for moderate and severe psychiatric dis-
orders. Carers are also responsible to dispense all the medicines prescribed by psychiatrists in
CAPS. They record all the activities related to the residents, in files kept in the residential facili-
ties type 2. Until 2010, approximately 9,000 people were living in psychiatric hospitals in Brazil
[21], and of this total, 6,349 were in the State of São Paulo [22]. In 2008, there were 160 people
living in psychiatric hospitals in the city of São Paulo (capital of the State of São Paulo), and
there was only one type 2 residential service and no type 1 residential facility. In 2011, at the be-
ginning of this study, 19 fully-staffed residential facilities (type 2) had been created in the city
of São Paulo, with 8 residents each.
Sampling: In 2008, two psychiatric hospitals were closed, and all the 160 inpatients were
transferred to the 20 existing residential facilities in the city of São Paulo or to a psychiatric
hospital in another city. No hospital records of these patients were available for data collection.
At the beginning of this study sampling, in 2010, there were 151 people discharged from the
two hospitals living in the residential facilities, and they were all selected to participate, accord-
ing to the following inclusion criteria: being a former resident of a psychiatric hospital for one
year or more and being able to understand and answer to the questions in the interviews.
Ethics
This study was approved by the Ethical Committee of the Secretary of Health of the city of Sao
Paulo. Carers and residents were adequately informed of all aspects regarding the participation
and the purpose of the study, providing a written consent prior to the interviews.
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Assessments Tools
Seven trained researchers interviewed the carers and residents. Instruments used to assess de-
mographic and clinical characteristics of the sample were: the Mini International Neuropsychi-
atric Interview (MINI) [23] for psychiatric diagnosis, the Clinical Global Impression- Severity
subscale (CGI-S), to assess symptoms severity [24], the Quality of Life Scale [25], the Social Be-
havior scale [26], the Independent Living Skills Scale[27]. All the assessment tools were trans-
lated and adapted to Portuguese.
Mini International Neuropsychiatric Interview (MINI). A validated Brazilian version
5.0 of Mini International Neuropsychiatric Interview [28] was used to assess lifetime and cur-
rent psychiatric diagnosis according to DSM-IV and ICD-10. This is a short semi-structured
diagnostic psychiatric interview developed to be used in clinical settings and for research [23].
Clinical Global Impression (CGI). In order to assess the severity of psychiatric symp-
toms, a validated Brazilian version of Clinical Global Impression—Severity (CGI-S) [29] was
applied. The score of the CGI-S based on behavior, global functioning and symptoms in the
last seven days. This scale is composed of five dimensions (positive, negative, cognitive, de-
pressive symptoms, and global). Scores range from 1 (normal) to 7 (the highest level of
severity) [24].
Quality of life. The Brazilian version of the Quality of life Scale [30], was used to assess
the resident quality of life in the last three weeks. This scale was developed for people with se-
vere mental disorders [25].
Functioning. The Independent Living Skills Survey [27], Brazilian version [31], was used
to assess functional living skills in the following domains: food, health, transport, self-care,
money management, work and global autonomy. It assesses the frequency of some behaviors
from “never occurs” (score 0) to “always occurs” (score 4) during the last month. Higher scores
suggest better functioning. This instrument was collected from the resident carer.
The Social Behavior Scale (SBS) [26], Brazilian version [32], was used to assess social func-
tioning. It includes 21 items which cover the daily social behavior in the last month (last 30
days), with information provided by the carer. Each item is scored from 0 (normal) to 4 (severe
behavior problem). Responses were categorised into a binary variable: normal social function-
ing (score of 0 or 1) and impaired social functioning (score of 2 or higher).
Costs. The Client Sociodemographic and Service Receipt Inventory (CSSRI) [33] is a
semi-structured instrument used to assess social and demographic data, accommodation data,
detailed information about treatment, professional visits, and social and health services utiliza-
tion. The CSSRI was translated to Portuguese and adapted to Brazilian context by Sousa et al
(Inventário Sociodemográfico de Utilização e Custos de Serviços—ISDUCS) [34]. The CSSRI
uses the patient and caregiver as information source.
Data Collection
Data were collected by semi-structured and structured interviews conducted by trained psychi-
atrists, directly with residents and carers; some additional information could be obtained from
the records available in the residential services. The SBS and the ILSS were applied with the car-
ers, as such scales rely on the information obtained from the carers' through the observation of
the residents' behavior.
The QLS, the MINI and the CGI-S were applied by psychiatrists directly with the residents.
The CSSRI was used to assess sociodemographic characteristics, previous and current occupa-
tional status, pattern of service uses, medicines and treatment received. Input to CSSRI were
obtained from the interviews with both carers and residents, as well as from the records.
The Economic Impact of Antipsychotic Polytherapy
PLOS ONE | DOI:10.1371/journal.pone.0124791 April 8, 2015 4 / 13
Definition of antipsychotic polytherapy
In this study we considered as antipsychotic polytherapy only those residents who were regu-
larly taking two or more antipsychotics (on a daily basis for oral and weekly/monthly in case of
depot) in the last 30 days previous to the interview. Data related to occasional antipsychotic
use were also collected, but was not considered polytherapy. Antipsychotic monotherapy was
defined as the use of only one antipsychotic, even when other non-antipsychotic drugs were
taken concomitantly. The combination of one antipsychotic with other drug classes (e.g. ben-
zodiazepines or antidepressants) was not considered an antipsychotic polytherapy in
this study.
Carers were responsible to dispense and supervise all the medicines taken by the residents,
and all the information was daily recorded. The antipsychotics were freely provided by the pub-
lic health system. The typical antipsychotics included haloperidol, chlorpromazine, levomepro-
mazine, periciazine, thioridazine, pimozide, pipotiazine depot and haloperidol depot. Atypical
antipsychotics included risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole
and clozapine.
Estimation of direct costs
A bottom-up approach was used for the estimation of direct costs, according to the public
health service provider perspective.
The CSSRI allows calculating health care costs using the modality of service or intervention
and the frequency of use. Direct costs of residential care, health care and treatments were calcu-
lated for each resident, for the year 2011.
Direct costs of the public health services for a 30-day period included: inpatient costs + out-
patient costs + emergency costs + medicine costs + psychosocial interventions (e.g. psychother-
apy, occupational therapy) costs + transport costs (ambulance).
Estimation of unit of costs
All costs were estimated for the year 2011 and the estimation of unit cost for medicines was
based on Brazilian Government Drug Price Database [35]. This database is available online for
public consultation and contains information about the costs of medicines per unit, as paid by
the government, according to the city, year, posology, pharmaceutical companies and institu-
tions. On average, the public health services buy medicines with prices up to 30% lower than
the market prices. The estimation of costs of antipsychotic polytherapy was calculated by sum-
ming up all costs of the antipsychotics regularly used in a 30-day period. The month of July,
2011 was used as reference for all the costs.
The estimation of cost for accommodation services was obtained directly from the residen-
tial managers. Information about residential costs included: electricity, gas, water, rent, repairs,
transport, human resources, food and house supplies and overhead. The estimation of costs for
public health services included hospital, emergency, outpatient and community services and
transport costs. The estimation of health services costs was based on the frequency of service
use in the previous month and on the calculation of the unit of cost: per visit (consultations)
and per day (hospitalization). Units of costs for health services were directly obtained from
service managers.
Statistical analyses
Two groups (antipsychotic polytherapy group and monotherapy group) were compared
through non parametric test (Chi square or Fischer exact test for categorical and nominal
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variables; significance level p<0.05) in terms of social and demographic characteristics, severity
of psychiatric symptoms, psychiatric diagnoses, medicines, drug association with benzodiaze-
pines, and type of antipsychotic used.
A multivariate linear regression analysis was fitted with direct costs of public health care per
person per month as dependent variable, and the number of antipsychotics, geographical loca-
tion of the facility, olanzapine use, and the length of time living in the residential facility were
included as covariates. Direct costs of public health care included costs with inpatient, outpa-
tient, emergency and community health services and treatment received in the previous month
(including all medicines).
Firstly, univariate linear regressions were built considering, individually, different covari-
ates, exploring the predictive of each measure on the costs of the residential facilities; then a
multivariate linear regression analysis was fitted only with those covariates statistically signifi-
cant in the univariate analysis (adopting significance level at 0.05).
Results
Four out of 151 residents refused to participate to this study. One hundred forty seven subjects
were included in the sample; 134 used antipsychotics regularly; the rate of antipsychotic poly-
therapy (two or more antipsychotics in daily use) was 38% (N = 56) (Table 1). Demographic
and clinical characteristics of the sample are also described in Table 1. There were no differ-
ences between those in use of antipsychotic polytherapy and monotherapy regarding sex, age,
education, severity of psychiatric symptoms, cognitive or negative symptoms, psychiatric diag-
nosis, pharmacological treatment for clinical somatic symptoms (hypertension, diabetes,
hypercholesterolemia) and benzodiazepine use. Antipsychotic polytherapy was correlated with
regular use of haloperidol, chlorpromazine, levomepromazine and depot antipsychotic but it
was not correlated with regular use of any other antipsychotic.
Overall, the mean (SD) length of time living in residential service was 35 (15.4) months. The
mean length of time living in residential service was significantly lower in polypharmacy group
than in monotherapy group (p = 0.011). The mean (SD) length of time living in psychiatric
hospitals were 115.39 (106.02), with no significant difference among them.
The mean (SD) number of individual psychotropics use was 3.37 (1.4), range 0 to 7, and the
mean (SD) number of individual antipsychotics was 1.45 (0.9), range 0 to 5.
Patterns of antipsychotic prescriptions were: 45.5% (n = 67) used at least one atypical anti-
psychotic, 64.6% (n = 95) used at least one typical antipsychotic, 14.2% (n = 21) used one typi-
cal and one atypical antipsychotic, 13.6% (n = 20) used two typical antipsychotics, and 10.8%
(n = 16) used three or more antipsychotics. The use of clozapine use was below 5% (Table 2).
Antipsychotics agents were also frequently associated with benzodiazepines, carbamaze-
pine, valproic acid, biperiden and promethazine (Table 2). The use of three or more psychotro-
pics (including pharmacological classes other than antipsychotics) was present in 75% of
the sample.
The total direct costs of public health care (health care, medicines and accommodation) for
a 30-day period were R$ 529,425.26. The total costs of accommodation were R$ 470,213.78, the
total costs of health care were R$ 24,058.45 and the costs of medicines were R$35,153.03. The
total costs of psychotropic were R$31,658.29. The costs of antipsychotics corresponded to
94.4% of the total psychotropic costs and to 49.5% of all health services use when excluding ac-
commodation costs of the residential facilities.
The mean monthly cost of antipsychotic polypharmacy per person varied according to the
type of antipsychotics combination: typical- atypical costs were R$515.64 (R$457.1), while
The Economic Impact of Antipsychotic Polytherapy
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Table 1. Demographic and clinical characteristics according to drug regimen (antipsychotic polytherapy or monotherapy) (N = 134)*.
Antipsychotic Polytherapy
(more than 1 antipsychotic)**
p (<0.05)
No Yes
Gender NS
male 41 26
female 37 30
Education NS
illiterate 15 09
primary 54 42
High school 08 02
College 01 02
Severity of psychiatric symptoms (CGI scale) NS
Mild or absent (0–2) 29 19
Moderate to severe (3–7) 49 37
Severity of cognitive symptoms (CGI scale) NS
Mild or absente (0–2) 32 24
Moderate to severe (3–7) 45 32
Negative symptoms (CGI scale) NS
Mild or absente (0–2) 45 30
Moderate to severe (3–7) 32 26
Psychiatric diagnosis NS
none 7 5
Alcohol or drugs problems 2 5
Psychosis 52 36
Psychosis and drug or alcohol problems 05 05
Psychotic depression 1 3
Depression 2 0
Bipolar mania 5 1
missing 4 1
Benzodiazepine use (previous month) NS
no 47 35
yes 31 21
Depot antipsychotic use (previous month) p<0.01
no 51 12
yes 27 44
Haloperidol use (previous month) p<0.01
no 51 12
yes 27 44
Chlorpromazine use (previous month) p<0.01
no 66 23
yes 12 33
Medicine use for metabolic syndrome
(hypertension, diabetes, cholesterol)
NS
no 44 40
yes 34 16
*Daily use of only one antipsychotic regardless of the association with drugs from other pharmacological classes,
**daily use of 2 or more antipsychotics
doi:10.1371/journal.pone.0124791.t001
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two-typical antipsychotics combination costs were R$8.72 (R$8.1). Olanzapine costs (n = 18)
corresponded to 51% of all psychotropic costs and 53% of the total antipsychotic costs.
A regression analysis was performed to explore a model in which direct public health care
costs (sum of health services, medicines and accommodation costs for a 30-day period) was the
dependent variable.
Table 3 shows the estimates (in R$) for different covariates on the costs of the residential fa-
cilities individually; hence, for each used covariate, a different linear regression was built. Four
covariates were statistically significant: the number of antipsychotics (for each antipsychotic
medicine, there is an increase in the residential facilities costs by R$175.14), the geographical
location of the facility (taking North zone as reference, the South region was more expensive by
R$484.29), and olanzapine use (taking other antipsychotic drugs as reference, olanzapine was
more expensive by R$1,014.91), and the length of time living in the residential facility (there is
a decrease of R$8.5 per month).
The outcome (direct costs of public health care) and its residual distributions were non-nor-
mal, as usually cost data are. However, even under non-normal error distribution linear regres-
sion and its estimates are BLUE (best linear unbiased estimator), being robust in a technical
sense; in other words, it is computable under almost any circumstance.
In Table 4, only the statistical significant isolated covariates were used to compose a multi-
variate linear regression with the four above cited covariates. The variance explained by the
four covariates together is 30.9%, remaining statistically significant the location in South region
and the regular use of olanzapine.
Table 2. Frequency, mean dose and unit of costs of most prescribed psychotropic (n = 147).
n (%) mean ±SD
(mg/day)
min/max
(mg/day)
Pill unit mg Unit cost
(per pill) R$
Total sum cost
per day R$
Chlorpromazine 45 (30.6) 250.6 ± 175.7 100–800 100 0.05 6.13
Haloperidol 78 (48.3) 4.0 ±5.7 1.0–25.0 5 0.01 1.57
Periciazine 11 (7.5) 25.7±20.0 5.0–60.0 1 0.01 3.84
Levomeprazine 06(4.1) 175.0±108.4 50–300 100 0.26 2.75
Thioridazine 01(0.68) - 300 100 0.18 0.06
Risperidone 21 (14.2) 4.3± 2.2 1.0–8.0 2 0.05 3.18
Olanzapine* 18 (12.2) 16.1±5.8 10–30 10 20.00 527.05
Clozapine 07 (4.8) 335.7±188.7 150–700 100 2.00 57.00
Quetiapine 09 (6.1) 455±113 300–600 200 7.33 224.45
Ziprasidone 07 (4.8) 160±65.3 80–240 80 7.20 103.16
Aripiprazole 02 (1.4) - 30 15 14.96 59.79
Haloperidol decanoate** 13 (8.8) 140.9±78.1 50–300** 50 0.04 1.54
Pipotiazine depot** 02 (1.4) - 50–75** 25 0.39 1.93
Total costs antipsychotics 989.44
Carbamazepine 30 (26.5) 663±294.5 200–1600 200 0.05 6.16
Valproic acid 22 (14.9) 1318±546.5 500–3000 500 0.04 2.26
Lithium 09(6.1) 857.1±320.7 300–1200 300 0.06 14.44
Biperiden 59 (40.0) 3.4±1.6 2–8 2 0.04 0.038
Prometazine 41 (27.9) 48.1±20.0 25–100 25 0.02 1.62
* Two values were used to olanzapine unit costs (R$10.00 and R$20.00).
** Dose per month
doi:10.1371/journal.pone.0124791.t002
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Table 5 shows the same model run under bootstrapping standard errors and normal based
95% confidence interval. Bootstrapping is a nonparametric statistical technique and it was used
because it does not require distribution assumption providing accurate inferences when the
data are not normally distributed.
Discussion
The rate of antipsychotic polypharmacy observed in our sample (38%) is within the range ob-
served in other studies [10,19,34,35]. The practice of polypharmacy was not correlated with the
severity of psychiatric symptoms, and in many cases would not be clinically justified. Given the
fact that approximately 30% of patients with psychosis are treatment-resistant [36], we can as-
sume that the prescription of clozapine in our sample was very low (<5%), opposed to all
guidelines recommendations. It is possible that some cases of switches and cross-titration have
been included, but the percentage might be minimal, as the data were based in the previous
month, and the patients were in chronic states, living in residential facilities for a mean period
of 3 years.
Table 3. Variables explaining health care costs (including residential facilities costs).
Estimate (R$) Standard Error p-value 95% CI r2
Age -5.715145 4.598371 0.216 -14.8036 3.373349 0.0105
Region South 484.2919 212.4812 0.024 64.25678 904.327 0.1099
Region East -270.1016 181.2046 0.138 -628.309 88.10557
Region Southeast 160.6955 161.2279 0.321 -158.022 479.4127
Region Center-west -277.9313 166.447 0.097 -606.966 51.10303
Lenght of time living in residential facility (months) -8.56085 3.877724 0.029 -16.225 -0.89669 0.0325
Olanzapine regular use (reference: other antypsychotics) 1014.918 165.3593 <0.001 688.0728 1341.763 0.2191
Number of antipsychotics* 175.1402 66.6714 0.01 43.36682 306.9135 0.0454
CGI score 8.826827 42.42076 0.835 -75.0161 92.66974 0.0003
SBS score -0.0748829 5.204153 0.989 -10.3607 10.21091 <0.00001
ILSS -3.294516 9.786797 0.737 -22.6377 16.04869 0.0008
Number of psychotropics 76.48758 43.18387 0.079 -8.8636 161.8388 0.0212
Lenght of time living in psychiatric hospital 0.9498517 0.53065 0.076 -0.09896 1.99866 0.0216
CGI: Clinical Global Impression; ILSS: Independent Living Skills Survey; SBS: Social Behavior Scale.
*Number of antipsychotics drugs refers to the number of antipsychotics regularly used (in this sample residents used 1 to 5 antipsychotics).
doi:10.1371/journal.pone.0124791.t003
Table 4. Multivariate linear regression of the the variables with most impact in residential costs.
Variables Estimate (R$) Standard Error p-value 95% CI
Location of the facility
South 520.9643 192.3548 0.008 140.6205 901.308
East -95.0554 167.5138 0.571 -426.281 236.1703
Southeast 119.185 151.3616 0.432 -180.103 418.4728
Center-west -11.9501 169.8589 0.944 -347.813 323.9125
Olanzapine regular use 945.8309 163.1091 <0.001 623.3146 1268.347
Number of antipsychotics 105.032 72.91305 0.152 -39.1393 249.2032
Length of time living in the facility (months) -4.05731 3.837409 0.292 -11.645 3.530418
doi:10.1371/journal.pone.0124791.t004
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Studies estimating the costs of antipsychotic polypharmacy are scarce. Instead, most studies
estimated the costs and cost-effectiveness of a specific monotherapy treatment. In this regard,
there is no evidence on the clinical superiority and on cost-effectiveness among antipsychotics,
with the exception for clozapine for severe psychotic disorders [37].
The choice of an antipsychotic therapy is strongly associated with health services costs.
Atypical antipsychotic monotherapy costs can be 167 times greater than typical antipsychotic
monotherapy costs [38]. A Brazilian cost-utility study reported that the economic impact of
olanzapine on public health services was greater than risperidone and haloperidol [39]. In our
study, almost half of direct health care costs (excluding the residential facilities) were due to an-
tipsychotic costs, with olanzapine costs corresponding to more than half of all psychotropic
costs. The unit cost of olanzapine was 400 times greater than the unit cost of risperidone in our
study. Typical antipsychotics have been recommended for low and midlle income countries be-
cause of the high costs of the atypicals [40], but it is not the case in Brazil. However, it is impor-
tant to take attention from policymakers about the consequences on buying new expensive
drugs without taking into account clinical effects and costs. Olanzapine in this case is only an
example, demonstrating the need for more cost-effectiveness studies exploring the range of
costs (threshold) that would be suitable for a country to afford and have relevant benefits. Our
study does not directly address cost-effectiveness but it is the first study in Brazil that measure
the effect of drug costs on services and to some extent, this can be an alert to discuss the ratio-
nal use of antipsychotic in different settings, considering low and middle income countries.
The lower rate of clozapine use is not justified by its cost; assuming the unit costs used in this
study, the cost of clozapine therapy (450mg/daily) plus four complete blood counts (CBC) per
month would be 50% of the costs of olanzapine therapy with a daily dose of 10 mg. Therefore,
protocols for rational prescription of antipsychotics might be crucial for optimizing budget allo-
cation. The reason for this low clozapine use should be better investigated, but one hypothesis is
the difficulty to guarantee the weekly blood counts needed with this drug, or maybe the lack of
training on its use. In Brazil, the choice of medicines is usually based on the physician’s prefer-
ences and the majority of professionals don’t take the costs and price into account.
A North-American study demonstrated that the combination of two antipsychotics added
annually U$4,244.00 per person when compared with monotherapy [40]. In our study, an anti-
psychotic polytherapy regimen added annually R$ 2,755.00 (approximately U$1,375.00) per
person for each antipsychotic added to the monotherapy.
The present study has some limitations. This was a cross-sectional study and data was col-
lected retrospectively, considering only the month previous to the interview; as a result, varia-
tions in the treatment over the year could not be accurately captured. Although the sample size
may be considered small, it is not a comparative study, and almost all residents discharged
Table 5. Multivariate linear regression of the the variables with most impact in residential costs (Bootstrapping).
Costs variables Observed coefﬁcient (R$) Bootstrap Standard error p-Value 95% CI
Residence location
South 440.4302 219.5569 0.045 10.10654–870.7538
East -201.0942 173.0284 0.245 -540.2237–138.0352
Southeast 38.98181 234.3863 0.868 -420.4069–498.3705
Center-west -179.2897 136.9568 0,191 -447.7201–89.14073
Olanzapine regular use 269.1076 95.10215 0.005 82.71086–455.5044
Number of antipsychotics 206.4687 108.099 0.056 -5.401545–418.3389
Length of time living in the facility (months) -2.673395 2.788026 0.338 -8.137825–2.791035
doi:10.1371/journal.pone.0124791.t005
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from two psychiatric hospitals in the city of Sao Paulo were included. It was not the aim of the
study to compare the rate of antipsychotic polytherapy in the residential facilities with the rate
found in other settings, such as hospitals and outpatients services.
The unit of costs for psychotropic was based on Federal Government database [35], and it
may not represent the real costs at a regional level. Although we simulated two values of unit
costs for olanzapine (R$ 10.00 and R$20.00) and results remained similar, sensitivity analyses
were not carried out to verify potential variation on other drug costs. This was not a cost-effec-
tiveness study, and decision of budged allocation should not be based only on costs. Moreover,
the harms of antipsychotic polytherapy were not considered, such as higher incidence of possi-
ble side-effects, such as weight gain and complications of drug interactions.
Conclusions
In summary, antipsychotic polytherapy adds a huge economic burden to health care systems,
and the choice of the antipsychotic may negatively impact the financial health care manage-
ment. The routine prescription of antipsychotics should be evaluated in terms of clinical bene-
fits, cost-effectiveness, potential harms and financial burden to health care. More research is
needed to explore how to monitor the rates of polytherapy, the costs and clinical consequences,
and also to establish clear criteria for the rational use of antipsychotic polytherapy. Such prac-
tices could contribute to a better budget planning in mental health care management and,
eventually, to better clinical outcomes. Considering the limited budget in low and middle in-
come countries like Brazil, this study raises the attention to the adoption of better strategies on
resource allocation, such as establishing a threshold for costs according to the benefits of newer
drugs, through cost-effectiveness comparisons.
Author Contributions
Conceived and designed the experiments: DR MK AS GG HCM AAC JJM. Performed the ex-
periments: DR MK AS GG AAC. Analyzed the data: DR MK AS GG HCM AAC JJM. Contrib-
uted reagents/materials/analysis tools: DR MK AS GG HCMAAC JJM. Wrote the paper: DR
MK AS GG HCMAAC JJM.
References
1. Huffman JC, Chang TE, Durham LE, Weiss AP. Antipsychotic polytherapy on an inpatient psychiatric
unit: how does clinical practice coincide with Joint Commission guidelines? General hospital psychiatry.
33: 501–8. doi: 10.1016/j.genhosppsych.2011.05.012 PMID: 21762994
2. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network
for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depres-
sive disorder in adults. III. Pharmacotherapy. Journal of affective disorders. 2009; 117 Suppl: S26–43.
doi: 10.1016/j.jad.2009.06.041 PMID: 19674794
3. Yatham LN, Kennedy SH, Parikh S V, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for
Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collab-
orative update of CANMAT guidelines for the management of patients with bipolar disorder: update
2013. Bipolar disorders. 2013; 15: 1–44. doi: 10.1111/bdi.12025 PMID: 23237061
4. Barnes TRE, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS drugs.
2011; 25: 383–99. doi: 10.2165/11587810-000000000-00000 PMID: 21476610
5. Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant corre-
lates of a long-standing clinical practice. The Psychiatric clinics of North America. 2012; 35: 661–81.
doi: 10.1016/j.psc.2012.06.007 PMID: 22929872
6. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia
PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia
bulletin. 2010; 36: 71–93. doi: 10.1093/schbul/sbp116 PMID: 19955390
7. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, GattazWF, et al. World Federation of Socie-
ties of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2:
The Economic Impact of Antipsychotic Polytherapy
PLOS ONE | DOI:10.1371/journal.pone.0124791 April 8, 2015 11 / 13
update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced
side effects. The world journal of biological psychiatry: the official journal of the World Federation of So-
cieties of Biological Psychiatry. 2013; 14: 2–44.
8. IPAP. International Psychiopharmacology Algorithm Project (IPAP): Schizophrenia Algorithm [Internet].
2006. Available: www.ipap.org/schiz/index.php
9. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medica-
tion Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of clinical
psychiatry. 2007; 68: 1751–62. PMID: 18052569
10. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizo-
phrenia. The International Journal of Neuropsychopharmacology. 2014; 17: 1083–1093. doi: 10.1017/
S1461145712000399 PMID: 22717078
11. Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug im-
prove clozapine treatment? Schizophrenia bulletin. 2009; 35: 458–68. doi: 10.1093/schbul/sbn030
PMID: 18436527
12. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability
of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:
951–62. doi: 10.1016/S0140-6736(13)60733-3 PMID: 23810019
13. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine
for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS
spectrums. 2013; 18: 82–9. doi: 10.1017/S1092852912000806 PMID: 23253621
14. Alessi-Severini S, Biscontri RG, Collins DM, Kozyrskyj A, Sareen J, Enns MW. Utilization and costs of
antipsychotic agents: a Canadian population-based study, 1996–2006. Psychiatric services (Washing-
ton, DC). 2008; 59: 547–53. doi: 10.1176/appi.ps.59.5.547 PMID: 18451015
15. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. Advantages and
disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008,
Nice. European neuropsychopharmacology: the journal of the European College of Neuropsychophar-
macology. 2009; 19: 520–32. doi: 10.1016/j.euroneuro.2009.04.003 PMID: 19411165
16. Lochmann van BennekomMWH, Gijsman HJ, Zitman FG. Antipsychotic polypharmacy in psychotic
disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. Journal of
psychopharmacology (Oxford, England). 2013; 27: 327–36. doi: 10.1177/0269881113477709 PMID:
23413275
17. Roh D, Chang J-G, Kim C-H, Cho H-S, An SK, Jung Y-C. Antipsychotic polypharmacy and high-dose
prescription in schizophrenia: a 5-year comparison. The Australian and New Zealand journal of psychi-
atry. 2014; 48: 52–60. doi: 10.1177/0004867413488221 PMID: 23671214
18. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching
from antipsychotic polypharmacy to monotherapy. The American journal of psychiatry. 2011; 168: 702–
8. doi: 10.1176/appi.ajp.2011.10060908 PMID: 21536693
19. Tomasi R, de Girolamo G, Santone G, Picardi A, Micciolo R, Semisa D, et al. The prescription of psy-
chotropic drugs in psychiatric residential facilities: a national survey in Italy. Acta psychiatrica Scandina-
vica. 2006; 113: 212–23. PMID: 16466405
20. Baandrup L, Sørensen J, Lublin H, Nordentoft M, Glenthoj B. Association of antipsychotic polyphar-
macy with health service cost: a register-based cost analysis. The European journal of health econom-
ics: HEPAC: health economics in prevention and care. 2012; 13: 355–63. doi: 10.1007/s10198-011-
0308-0 PMID: 21452062
21. Ministerio da Saúde. Reforma Psiquiátrica e Política de Saúde Mental no Brasil. In: Conferência Re-
gional de Reforma dos Serviços de Saúde Mental: 15 anos depois de Caracas [Internet]. 2005. Avail-
able: http://bvsms.saude.gov.br/bvs/publicacoes/Relatorio15_anos_Caracas.pdf
22. Aranha e Silva A, Pitta AMF, Covre EM, Souza JC, Oliveira MAF, Nicácio MFS, et al. Desafios para a
desinstitucionalização: censo psicossocial dos moradores em hospitais psiquiátricos do Estado de
São Paulo [Internet]. São Paulo, SP: FUNDAP-Secretaria da Saúde do Estado de São Paulo; 2008.
Available: http://pfdc.pgr.mpf.mp.br/atuacao-e-conteudos-de-apoio/publicacoes/saude-mental/censo_
psicossocialSP.pdf
23. Sheehan D V, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International
Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychi-
atric interview for DSM-IV and ICD-10. The Journal of clinical psychiatry. 1998; 59 Suppl 2: 22–33;quiz
34–57.
24. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-
Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophre-
nia. Acta psychiatrica Scandinavica Supplementum. 2003; 16–23. PMID: 12755850
The Economic Impact of Antipsychotic Polytherapy
PLOS ONE | DOI:10.1371/journal.pone.0124791 April 8, 2015 12 / 13
25. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizo-
phrenic deficit syndrome. Schizophrenia bulletin. 1984; 10: 388–98. PMID: 6474101
26. Wykes T, Sturt E. The measurement of social behaviour in psychiatric patients: an assessment of the
reliability and validity of the SBS schedule. The British journal of psychiatry: the journal of mental sci-
ence. 1986; 148: 1–11. PMID: 3082403
27. Wallace CJ, Liberman RP, Tauber R, Wallace J. The independent living skills survey: a comprehensive
measure of the community functioning of severely and persistently mentally ill individuals. Schizophre-
nia bulletin. 2000; 26: 631–58. PMID: 10993403
28. Amorim P. Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para
diagnóstico de transtornos mentais. Revista Brasileira de Psiquiatria. 2000; 22: 106–115.
29. Lima MS de, Soares BG de O, Paoliello G, Machado Vieira R, Martins CM, Mota Neto JI da, et al. The
Portuguese version of the Clinical Global Impression-Schizophrenia Scale: validation study. Revista
brasileira de psiquiatria. 2007; 29: 246–9. PMID: 17891261
30. Cardoso CS, Bandeira M, Caiaffa WT, Fonseca JO. Quality of life scale for patients with schizophrenia,
Brazilian version: transcultural adaptation to Brazil. Jornal Brasileiro de Psiquiatria. 2002; 51: 31–38.
31. Bandeira M, Lima LA, Gonçalves S. Qualidades psicométricas no papel da Escala de Habilidades de
Vida Independente de pacientes psiquiátricos (ILSS-BR). Rev Psiquiatr Clin. 2003; 30: 121–125.
32. Lima LA, Gonçalves S, Pereira BB, Lovisi GM. The measurement of social disablement and assess-
ment of psychometric properties of the Social Behaviour Schedule (SBS-BR) in 881 Brazilian long-stay
psychiatric patients. The International journal of social psychiatry. 2006; 52: 101–9. PMID: 16615243
33. Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, vanWijngaarden B. Client Socio-Demo-
graphic and Service Receipt Inventory—European Version: development of an instrument for interna-
tional research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains
and Needs. The British journal of psychiatry Supplement. 2000; s28–33. PMID: 10945075
34. Sousa A, Cardoso A, Gregorio G, Mari JJ, Razzouk D. Standardized tool for measurement of health
services costs and utilization in a sample with mental disorders: translation, cultural adaptation and
interrater reliability of the client sociodemographic and service receipt inventory—Brazilian version.
ISPOR 4th Latin America Conference. Buenos Aires, Argentina: International Society for Pharmacoe-
conomics and Outcomes Research; 2013.
35. Ministerio da Saúde. Banco de Preços [Internet]. 2011. Available: http://portalsaude.saude.gov.br/
index.php?option = com_content&view = article&id=6160&Itemid=286
36. Elkis H. Treatment-resistant schizophrenia. The Psychiatric clinics of North America. 2007; 30: 511–33.
PMID: 17720034
37. Knapp M, Razzouk D. Economics and Schizophrenia. In: Kasper S, Papadimirou G, editors. Schizo-
phrenia: Biopsychosocial approaches and current challenges. Informa Healthcare New York, USA;
2009. pp. 347–361.
38. Razzouk D, Sousa A, Oliveira G, Cardoso A, JJ M. The impact of antipscyhotics polipharmacy on
health care costs of people with mental disorders in Sao Paulo City, Brazil. Value in Health. 2013; 16:
A694–A695. doi: 10.1016/j.jval.2013.03.007 PMID: 23693162
39. Lindner LM, Marasciulo AC, Farias MR, Grohs GEM. Economic evaluation of antipsychotic drugs for
schizophrenia treatment within the Brazilian Healthcare System. Revista de saúde pública. 2009; 43
Suppl 1: 62–9. PMID: 23559050
40. Loosbrock DL, Zhao Z, Johnstone BM, Morris LS. Antipsychotic medication use patterns and associat-
ed costs of care for individuals with schizophrenia. The journal of mental health policy and economics.
2003; 6: 67–75. PMID: 14578539
The Economic Impact of Antipsychotic Polytherapy
PLOS ONE | DOI:10.1371/journal.pone.0124791 April 8, 2015 13 / 13
